Cor Vasa 2011, 53(6-7):365-368 | DOI: 10.33678/cor.2011.089

Chemokine MCP-1 and atherosclerosis

Jana Petřková
I. interní klinika - kardiologická, Fakultní nemocnice Olomouc a Lékařská fakulta Univerzity Palackého, Olomouc, Česká republika

Atherosclerosis has been defined as systemic, chronic inflammatory disease characterized by degenerative processes and extracellular accumulation of lipids.
Inflammation is important pathogenetic mechanism of atherosclerosis whose clinical manifestations comprise diseases of distinct location. Chemotactic cytokines and their receptors play key role in atherogenesis. Expression and function of these molecules is influenced by variability (polymorphisms) in their encoding genes.
Translational research in pathobiology of cardiovascular disorders aims at extending the current spectrum of laboratory parameters with new markers, which could help us to define the patients at risk more precisely and to determine disease course more accurately. Investigation of atherosclerosis candidate molecules is one of the possible routes to this aim. Mononuclear chemoattractant MCP-1 (CCL2) and its receptor CCR2 represent such molecules.

Keywords: Atherosclerosis; Inflammation; Mononuclear chemoattractant MCP-1 (CCL2); Receptor CCR2

Published: June 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petřková J. Chemokine MCP-1 and atherosclerosis. Cor Vasa. 2011;53(6-7):365-368. doi: 10.33678/cor.2011.089.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Chamberlain J, Evans D, King A, et al. Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. Am J Pathol 2006;168:1396-1403. Go to original source... Go to PubMed...
    2. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508-519. Go to original source... Go to PubMed...
    3. Topol EJ, Smith J, Plow EF, Wang QF. Genetic susceptibility to myocardial infarction and coronary artery disease. Hum Mol Genet 2006;15(Spec No 2): R117-123. Go to original source... Go to PubMed...
    4. Ollier WE. Cytokine genes and disease susceptibility. Cytokine 2004; 28:174-178. Go to original source... Go to PubMed...
    5. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565. Go to original source... Go to PubMed...
    6. Armani A, Becker RC. The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part II. Am Heart J 2005;149:977-983. Go to original source... Go to PubMed...
    7. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207. Go to original source... Go to PubMed...
    8. Segers D, Garcia-Garcia HM, Cheng C, et al. A primer on the immune system in the pathogenesis and treatment of atherosclerosis. EuroIntervention 2008;4:378-390. Go to original source... Go to PubMed...
    9. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002;91:281-291. Go to original source... Go to PubMed...
    10. Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 2006;7:243. Go to original source... Go to PubMed...
    11. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991;88: 1121-1127. Go to original source... Go to PubMed...
    12. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990;87: 5134-5138. Go to original source... Go to PubMed...
    13. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004;95:858-866. Go to original source... Go to PubMed...
    14. Veillard NR, Steffens S, Pelli G, et al. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation 2005;112:870-878. Go to original source... Go to PubMed...
    15. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998;2:275-281. Go to original source... Go to PubMed...
    16. Aiello RJ, Bourassa PA, Lindsey S, et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1999;19:1518-1525. Go to original source... Go to PubMed...
    17. Inoue S, Egashira K, Ni W, et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 2002;106:2700-2706. Go to original source...
    18. Salcedo R, Ponce ML, Young HA, et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000;96:34-40. Go to original source...
    19. Doyle B, Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol 2007;49:2073-2080. Go to original source... Go to PubMed...
    20. Robinson SC, Scott KA, Balkwill FR. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur J Immunol 2002;32:404-412. Go to original source...
    21. Schecter AD, Rollins BJ, Zhang YJ, et al. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem 1997;272:28568-28573. Go to original source... Go to PubMed...
    22. Lutgens E, Faber B, Schapira K, et al. Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody. Circulation 2005;111:3443-3452. Go to original source... Go to PubMed...
    23. Mehrabian M, Sparkes RS, Mohandas T, et al. Localization of monocyte chemotactic protein-1 gene (SCYA2) to human chromosome 17q11.2-q21.1. Genomics 1991;9:200-203. Go to original source... Go to PubMed...
    24. McDermott DH, Yang Q, Kathiresan S, et al. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 2005;112:1113-1120. Go to original source... Go to PubMed...
    25. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52:145-176. Go to PubMed...
    26. Petrkova J, Szotkowska J, Hermanova Z, et al. Monocyte chemoattractant protein-1 in patients with peripheral arterial disease. Mediators Inflamm 2004;13:39-43. Go to original source... Go to PubMed...
    27. Arakelyan A, Petrkova J, Hermanova Z, et al. Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction. Mediators Inflamm 2005;3(2005):175-179. Go to original source... Go to PubMed...
    28. Cermakova Z, Petrkova J, Arakelyan A, et al. The MCP-1-2518 (A to G) single nucleotide polymorphism is not associated with myoacardial infarction in the Czech population. Int J Immunogenet 2005;32:315-318. Go to original source... Go to PubMed...
    29. Bucova M, Lietava J, Mrazek F, et al. Association of chronic stable angina pectoris with MCP-1-2518 A/G single nucleotide polymorphism in the Slovak population. Clin Chim Acta 2008;392:71-72. Go to original source... Go to PubMed...
    30. Flossmann E, Schulz UG, Rothwell PM. Potential confounding by intermediate phenotypes in studies of the genetics of ischaemic stroke. Cerebrovasc Dis 2005;19:1-10. Go to original source... Go to PubMed...
    31. Macek M. Jr., Krebsová A, Macek M, et al. Current possibilities of prenatal and postnatal molecular genetic diagnosis of cystic fibrosis in Czech and Slovak Republics. Česko-Slovenská Pediatrie 1997;52:557-564.
    32. Petrkova J, Cermakova Z, Drabek J, et al. CC chemokine receptor (CCR)2 polymorphism in Czech patients with myocardial infarction. Immunol Lett 2003;88:53-55. Go to original source... Go to PubMed...
    33. Ortlepp JR, Vesper K, Mevissen V, et al. Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age. J Mol Med 2003;81:363-367. Go to original source... Go to PubMed...
    34. Ortlepp JR, Krantz C, Kimmel M, et al. Additive effects of the chemokine receptor 2, vitamin D receptor, interleukin-6 polymorphisms and cardiovascular risk factors on the prevalence of myocardial infarction in patients below 65 years. Int J Cardiol 2005;105:90-95. Go to original source... Go to PubMed...
    35. Martinovic I, Abegunewardene N, Seul M, et al. Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease. Circ J 2005;69:1484-1489. Go to original source... Go to PubMed...
    36. Nylaende M, Kroese A, Stranden E, et al. Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc Med 2006;11:21-28. Go to original source... Go to PubMed...
    37. Aukrust P, Yndestad A, Smith C, et al. Chemokines in cardiovascular risk prediction. Thromb Haemost 2007;97:748-754. Go to original source... Go to PubMed...
    38. Gonzalez-Quesada C, Frangogiannis NG. Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes. Curr Atheroscler Rep 2009;11:131-138. Go to original source... Go to PubMed...
    39. Szalai C, Duba J, Prohászka Z, et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients. Atherosclerosis 2001;158:233-239. Go to original source... Go to PubMed...
    40. Simeoni E, Winkelmann BR, Hoffmann MM, et al. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J 2004;25:1438-1446. Go to original source... Go to PubMed...
    41. Bjarnadottir K, Eiriksdottir G, Aspelund T, Gudnason V. Examination of genetic effects of polymorphisms in the MCP-1 and CCR2 genes on MI in the Icelandic population. Atherosclerosis 2006;188:341-346. Go to original source... Go to PubMed...
    42. Medica I, Kastrin A, Mayer A, Peterlin B. Role of genetic polymorphisms in ACE and TNF-alpha gene in sarcoidosis: a meta-analysis. J Hum Genet 2007;52:836-847. Go to original source... Go to PubMed...
    43. Lee YH, Ji JD, Bae SC, Song GG. Association between TNFalpha -308 and-238G/A polymorphisms and shared epitope status and responsiveness to TNFalpha blockers in rheumatoid arthritis: a metaanalysis update. J Rheumatol 2009;4:740-746. Go to original source...
    44. Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 2003;108:250-252. Go to original source... Go to PubMed...
    45. Ray KK, Cannon CP, Cairns R, et al. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2009;29:424-430. Go to original source... Go to PubMed...
    46. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008;7:827-840. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes